Top

Published in:

Open Access 01-06-2018 | Preclinical study

A retrospective prognostic evaluation analysis using the 8th edition of the American Joint Committee on Cancer staging system for breast cancer

Authors: Sae Byul Lee, Guiyun Sohn, Jisun Kim, Il Yong Chung, Jong Won Lee, Hee Jeong Kim, Beom Seok Ko, Byung Ho Son, Sei-Hyun Ahn

Published in: Breast Cancer Research and Treatment | Issue 2/2018

Abstract

Purpose

Breast cancer is a group of diseases with different intrinsic molecular subtypes. However, anatomic staging alone is insufficient to determine prognosis. The present study analyzed the prognostic value of the American Joint Committee for Cancer (AJCC) 8th edition cancer staging system.

Methods

This retrospective, single-center study included breast cancer cases diagnosed from January 1999 to December 2008. We restaged patients based on the 8th edition AJCC cancer staging system and analyzed the prognostic value of the anatomic and prognostic staged groups. Follow-up data including disease-free survival (DFS), overall survival (OS), and clinic-pathological data were collected to analyze the differences between the two staging subgroups.

Results

The study enrolled 7458 breast cancer patients with a 98.7-month median follow-up. Both the 5-year DFS and OS were significantly different between the anatomic and prognostic staged groups. The 5-year OS according to disease subtype was as follows: hormone receptor-positive/human epidermal growth factor receptor 2-negative [HR(+)/HER2(−)], 90.9%; HR(+)/HER2(+), 84.7%; HR(−)/HER2(+), 81.1%; and HR(−)/HER2(−), 80.9%. According to the anatomic stage, the 5-year OS of patients with stage III HR(+)/HER2(−) disease was superior to that of patients with stage II HR(−)/HER2(−) disease (88.3 vs. 86.5%). Per the prognostic stage, both the 5-year DFS and OS rates of patients with stage II HR(−)/HER2(−) disease were higher than those of patients with stage III HR(+)/HER2(−) disease (90.1 and 94.3% vs. 79.1 and 88.9%).

Conclusions

The prognostic staging system is a refined version of the anatomic staging system and encourages a more personalized approach to breast cancer treatment.

Zhou B, Xu L, Ye J, Xin L, Duan X, Liu Y (2017) The prognostic value of the 8th edition of the American Joint Committee on Cancer (AJCC) staging system in her2-enriched subtype breast cancer, a retrospective analysis. Anticancer Res 37:4615–4621. https://doi.org/10.21873/anticanres.11862 PubMed

Xu L, Li JH, Ye JM, Duan XN, Cheng YJ, Xin L, Liu Q, Zhou B, Liu YH (2017) A retrospective survival analysis of anatomic and prognostic stage group based on the American Joint Committee on Cancer 8th edition cancer staging manual in luminal b human epidermal growth factor receptor 2-negative breast cancer. Chin Med J (Engl) 130:1945–1952CrossRef

Amin MB, Greene FL, Edge SB et al (2017) The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin 67:93–99. https://doi.org/10.3322/caac.21388 CrossRefPubMed

Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ (2011) Strategies for subtypes–dealing with the diversity of breast cancer: highlights of the St. Gallen international expert consensus on the primary therapy of early breast cancer 2011. Ann Oncol 22:1736–1747. https://doi.org/10.1093/annonc/mdr304 CrossRefPubMedPubMedCentral

Carey LA, Perou CM, Livasy CA et al (2006) Race, breast cancer subtypes, and survival in the Carolina breast cancer study. JAMA 295:2492–2502. https://doi.org/10.1001/jama.295.21.2492 CrossRefPubMed

Sorlie T, Perou CM, Tibshirani R et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98:10869–10874. https://doi.org/10.1073/pnas.191367098 CrossRefPubMedPubMedCentral

Perou CM, Sorlie T, Eisen MB et al (2000) Molecular portraits of human breast tumours. Nature 406:747–752. https://doi.org/10.1038/35021093 CrossRefPubMed

Spitale A, Mazzola P, Soldini D, Mazzucchelli L, Bordoni A (2009) Breast cancer classification according to immunohistochemical markers: clinicopathologic features and short-term survival analysis in a population-based study from the South of Switzerland. Ann Oncol 20:628–635. https://doi.org/10.1093/annonc/mdn675 CrossRefPubMed

Ye J, Wang W, Xu L et al (2017) A retrospective prognostic evaluation analysis using the 8th edition of American Joint Committee on Cancer (AJCC) cancer staging system for luminal a breast cancer. Chin J Cancer Res 29:351–360. https://doi.org/10.21147/j.issn.1000-9604.2017.04.08 CrossRefPubMedPubMedCentral

10.

Edge SB, Compton CC, Xu L (2010) The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 17:1471–1474. https://doi.org/10.1245/s10434-010-0985-4 CrossRefPubMed

11.

Giuliano AE, Connolly JL, Edge SB, Mittendorf EA, Rugo HS, Solin LJ, Weaver DL, Winchester DJ, Hortobagyi GN (2017) Breast Cancer-Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 67:290–303. https://doi.org/10.3322/caac.21393 CrossRefPubMed

12.

Bauer K, Parise C, Caggiano V (2010) Use of ER/PR/HER2 subtypes in conjunction with the 2007 St Gallen consensus statement for early breast cancer. BMC Cancer 10:228. https://doi.org/10.1186/1471-2407-10-228 CrossRefPubMedPubMedCentral

13.

Diab SG, Hilsenbeck SG, de Moor C, Clark GM, Osborne CK, Ravdin PM, Elledge RM (1998) Radiation therapy and survival in breast cancer patients with 10 or more positive axillary lymph nodes treated with mastectomy. J Clin Oncol 16:1655–1660. https://doi.org/10.1200/jco.1998.16.5.1655 CrossRefPubMed

14.

Caldarella A, Crocetti E, Bianchi S, Vezzosi V, Urso C, Biancalani M, Zappa M (2011) Female breast cancer status according to ER, PR and HER2 expression: a population based analysis. Pathol Oncol Res 17:753–758. https://doi.org/10.1007/s12253-011-9381-z CrossRefPubMed

15.

Zarcone M, Amodio R, Campisi I, Cusimano R, Dolcemascolo C, Miceli V, Traina A, Macaluso M (2009) Application of a new classification to a breast tumor series from a population-based cancer registry: demographic, clinical, and prognostic features of incident cases, Palermo Province, 2002–2004. Ann N Y Acad Sci 1155:222–226. https://doi.org/10.1111/j.1749-6632.2008.03693.x CrossRefPubMed

16.

Kim HJ, Kim HJ, Lee SB, Moon HG, Noh WC, Cho YU, Yoo Y, Ahn SH (2015) A proposal for a new classification of T4 breast cancer as stage IIIC: a report from the Korean breast cancer Society. Breast Cancer Res Treat 153:153–160. https://doi.org/10.1007/s10549-015-3501-5 CrossRefPubMed

17.

Woodward WA, Strom EA, Tucker SL et al (2003) Changes in the 2003 American Joint Committee on Cancer staging for breast cancer dramatically affect stage-specific survival. J Clin Oncol 21:3244–3248. https://doi.org/10.1200/jco.2003.03.052 CrossRefPubMed

18.

Saphner T, Tormey DC, Gray R (1996) Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 14:2738–2746. https://doi.org/10.1200/jco.1996.14.10.2738 CrossRefPubMed

19.

Park S, Koo JS, Kim MS, Park HS, Lee JS, Lee JS, Kim SI, Park BW (2012) Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry. Breast 21:50–57. https://doi.org/10.1016/j.breast.2011.07.008 CrossRefPubMed

20.

Puig-Vives M, Sanchez MJ, Sanchez-Cantalejo J et al (2013) Distribution and prognosis of molecular breast cancer subtypes defined by immunohistochemical biomarkers in a Spanish population-based study. Gynecol Oncol 130:609–614. https://doi.org/10.1016/j.ygyno.2013.05.039 CrossRefPubMed

Title: A retrospective prognostic evaluation analysis using the 8th edition of the American Joint Committee on Cancer staging system for breast cancer
Authors: Sae Byul Lee
Guiyun Sohn
Jisun Kim
Il Yong Chung
Jong Won Lee
Hee Jeong Kim
Beom Seok Ko
Byung Ho Son
Sei-Hyun Ahn
Publication date: 01-06-2018
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 2/2018
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-018-4682-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2018

Chronic postsurgical pain following breast reconstruction: a commentary and critique

A novel patient-derived xenograft model for claudin-low triple-negative breast cancer

Complications following immediate compared to delayed deep inferior epigastric artery perforator flap breast reconstructions

Rapid review: radiomics and breast cancer

Lymph drainage of the upper limb and mammary region to the axilla: anatomical study in stillborns

A comprehensive tool for measuring mammographic density changes over time

Keynote webinar | Spotlight on antibody–drug conjugates in cancer